Risks

ARMP’s current and quick ratios of 0.11 versus peer biotech norms near or above 1.0 indicate severe near-term liquidity strain, increasing dilution or financing risk.

Negative net debt to EBITDA and interest coverage metrics suggest limited balance-sheet flexibility versus better-capitalized peers, constraining execution if clinical or regulatory timelines slip.

A 280-day DSO and deeply negative cash conversion cycle imply slow cash collection relative to peers, raising working-capital pressure and reducing operating runway.

Payables stretched to 416 days versus more normalized peer terms signal supplier dependence and potential disruption risk, especially if vendors tighten credit.

Opportunities

If ARMP can convert receivables and working capital more efficiently than small-cap peers, the current cash conversion profile offers meaningful upside to liquidity preservation.

The absence of meaningful debt service burden versus levered peers could support capital allocation flexibility if operating cash generation improves, though current liquidity remains the binding constraint.

Any successful stabilization of working capital would have a larger relative impact than for better-funded peers, because ARMP’s low liquidity base makes incremental improvement more visible.

Overall Score

ARMP’s forward positioning is dominated by acute liquidity and working-capital risk versus peers, while limited upside exists only if cash efficiency improves materially.